29 mei 2019: 

Koemende maand is er weer ASCO 2019. Hier een aantal aanbevolen abstracten over prostaatkanker door artsen die zelf voor ASCO werken. Klik op de nummers voor de abstracten.

Published in Oncology and 1 other channel 

Expert Opinion / Conference Coverage · May 28, 2019

ASCO 2019: Abstract Recommendations From Dr. Brian Lewis for Prostate Cancer

Session: Genitourinary (Prostate) Cancer
Friday May 31, 2019; 2:45 PM–5:45 PM 

5001 Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475). C Carrie, N Magné, P Burban-Provost, et al

Session: Genitourinary (Prostate) Cancer
Saturday June 1, 2019; 1:15 PM–4:15 PM

5013 Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT). PJ Vlachostergios, MJ Niaz, SA Mosallaie, et al

5017 Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC). G Baciarello, R Delva, G Gravis, et al

5022 External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). S Halabi, S Dutta, JC Araujo, et al

5035 Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis. AO Sartor, AJ Armstrong, C Ahaghotu, et al 

5046 Abiraterone acetate plus prednisone (AA+P) without continuing LHRH-therapy in patients with metastatic chemotherapy: Naive castrations-resistant prostate cancer—Results from the SPARE-trial (NCT02077634). CH Ohlmann, C Ruessel, R Zillman, et al

5048 ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC). AJ Armstrong, RZ Szmulewitz, DP Petrylak, et al

5049 Suppression of testosterone production using abiraterone acetate (AA) with or without androgen deprivation therapy (ADT) in metastatic castration resistant prostate cancer (mCRPC). GG Jha, E Jeff

5056 Impact of germline DNA-repair gene BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-naïve prostate cancer: A single center analysis. VB Matveev, L Lyubchenko, A Kirichek

5058 AR changes in circulating-tumor DNA (ctDNA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone. MW Moses, E Ledet, C Manogue, et al 

aanbevolen abstracten prostaatkanker ASCO 2019.


Plaats een reactie ...

Reageer op "Aanbevolen abstracten voor prostaatkanker van ASCO 2019. Artikel geplaatst 29 mei 2019"


Gerelateerde artikelen
 

Gerelateerde artikelen

ASCO 2021: Aanbevolen abstracten >> ASCO 2020: Aanbevolen abstracten >> Aanbevolen abstracten voor >> Belangrijke abstracten van >> ASCO GU 2022: Abstracten gerelateerd >>